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REVIEW ARTICLE 
Sodium-glucose co-transporter 2 (SGLT2) inhibitors  
Simon Mifsud, Emma Louise Schembri, Annalisa Montebello, Mark Gruppetta
Type 2 diabetes mellitus is a progressive metabolic disorder. Marked 
hyperglycaemia leads to serious vascular complications. Hence, 
addressing this modifiable risk factor is of paramount importance. 
Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a 
relatively new class of antidiabetic agents. They offer an 
intermediate glucose-lowering effect and through other pleiotropic 
effects provide cardiac and renal benefits. This review focuses on the 
mechanism of action, benefits and adverse effects of SGLT2 
inhibitors. The authors also delineate the ideal type 2 diabetic 
candidate to receive SGLT2 inhibitors. This is critical as SGLT2 
inhibitors should not be used in a ‘one-size-fits-all approach’ but their 
use should be individualized based on certain patient characteristics. 
This patient-centred approach aims at maximizing the benefits and 
reduce the risks associated with SGLT2 inhibitors.  
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INTRODUCTION 
Type 2 diabetes mellitus is a complex 
metabolic disorder in which hyperglycaemia 
occurs as a result of a number of 
pathophysiological disturbances. DeFronzo 
refers to these pathophysiological processes 
as the ominous octet. These are summarized in 
Table 1.1 Marked hyperglycaemia is associated 
with long term end organ damage due to 
microvascular and macrovascular 
complications.2 Good glycaemic control 
reduces the risk of onset and progression of 
such complications.3 However, achieving 
optimal glycaemic control remains a challenge. 
Sodium-glucose co-transporter 2 (SGLT2) 
inhibitors are a relatively new class of oral 
antidiabetic agents.4 They offer a new strategy 
for achieving glycaemic control and have been 
associated with cardiovascular and renal-
outcome benefits.5 Despite their effectiveness 
in the treatment of type 2 diabetes, a number 
of adverse effects have been linked to SGLT2 
inhibitors.6 Hence, SGLT2 inhibitor therapy re-
enforces the importance of personalized 
patient-centred management. The latter 
approach reduces the risks of adverse effects 
by the analysis of patient’s characteristics prior 
to the prescription of such agents.7 
THE PHYSIOLOGICAL ACTIONS OF SGLT2  
INHIBITORS 
The kidneys play a pivotal role in glucose 
handling. In healthy adults, they filter 160-
180g of glucose per day.8 This filtered glucose 
is then reabsorbed and returned to the 
systemic circulation via the proximal 
convoluted tubule. 90% of renal glucose 
reabsorption is mediated through SGLT2 
activity.9  SGLT2 is a high capacity, low affinity 
transporter distributed over the luminal 
surface of the S1 and S2 segment of the 
proximal convoluted tubule.10 The residual  
filtered glucose is reabsorbed by the low 
capacity, high affinity sodium-glucose co-
transporter 1 (SGLT1).11 
Hyperglycaemia increases the filtered and 
reabsorbed glucose up to two-fold.8 
Furthermore, in type 2 diabetes, SGLT2 activity 
seems to be upregulated due to increased 
expression of the SGLT2 transporter genes. 
This leads to increased glucose reabsorption 
with resultant hyperglycaemia.4, 12 
SGLT2 inhibitors block the reabsorption of the 
filtered glucose through the SGLT2 in the 
proximal convoluted tubule, hence inducing 
glycosuria and osmotic diuresis. This leads to 
decreased glycated haemoglobin levels, body 
weight and systolic and diastolic blood 
pressure.13-14 
SGLT2 has recently also been discovered on 
pancreatic α-cells.15 Inhibition of these 
transporters by SGLT2 inhibitors, blocks 
glucose influx into the pancreatic α-cells, 
leading to increased glucagon secretion.15 This 
process blunts the SGLT2 inhibitors’ 
hypoglycaemic effect, as glucagon promotes 
endogenous glucose production (via 
glycogenolysis and gluconeogenesis).16 
Another postulated mechanism behind 
glucagon secretion is the compensatory 
glucagon release that occurs in response to 
the acute decline in serum glucose 
concentration due to the induced glycosuria 
secondary to SGLT2 inhibition.17 Overall SGLT2 
inhibition results in a reduced insulin: glucagon 
ratio. This reduced insulin: glucagon ratio 
meets two of the pathophysiological 
mechanisms making up the ominous octet 
leading to hyperglycaemia (Table 1) and hence 
one would expect SGLT2 inhibitors to increase 
glucose levels. However, there are two 
mechanisms by which this ratio may actually 
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benefit type 2 diabetes patients utilising 
SGLT2 inhibitors.  
 
Table 1 Pathophysiological Mechanisms 
making up the Ominous Octet 
(Adapted from DeFronzo).1 
 
 
 
 
 
 
 
 
 
 
 
 
In fact this reduced insulin: glucagon ratio has 
been termed as the ‘Robin-Hood effect’ by one 
review paper.18 SGLT2 inhibition lowers insulin 
secretion, hence preventing unnecessary 
glucose utilization by peripheral tissues 
creating a ‘pseudo-fasting’ state and thus 
encourages lipolysis to generate free fatty 
acids.18 Through β-oxidation and the citric acid 
cycle, energy is released from fatty acid 
metabolism. In addition, when the processing 
capacity of the citric acid cycle is overwhelmed, 
free fatty acid metabolism leads to the 
biosynthesis of ketone bodies. Ketone bodies 
are another alternative energy substrate. 
Hence, SGLT2 inhibition favours the switch 
from carbohydrate to lipid metabolism. This 
also contributes to weight loss in the long 
term.18 
Furthermore, the increased glucagon 
secretion, results in increased endogenous 
glucose production. Additionally, the reduced 
insulin secretion prevents unnecessary 
glucose uptake by peripheral tissues, allowing 
more glucose to be filtered through the 
glomerulus. Glucose reabsorption via the 
SGLT2 in the proximal convoluted tubule is 
however inhibited by SGLT2 inhibitors. The 
energetic costs of gluconeogenesis and caloric 
loss of glycosuria promote further weight 
loss.19 
As aforementioned, the hyperglycaemia in 
type 2 diabetes leads to an increase in the 
concentration of filtered glucose in the 
proximal convoluted tubules. This results in 
overactivity of the SGLT2 and SGLT1 
transporters with resultant increased glucose 
and sodium reabsorption. The tubular fluid at 
the macula densa in the distal convoluted 
tubule will thus have a reduced sodium 
concentration. As a response, the tubulo-
glomerular feedback system leads to renin-
angiotensin-aldosterone system (RAAS) 
activation and afferent arteriole 
vasodilatation, with glomerular hyperfiltration 
being the end result.20  
The vasodilatory effect on the afferent 
arteriole is predominantly responsible for the 
glomerular hyperfiltration observed in 
diabetes.12 Glomerular hyperfiltration 
accompanied by glomerular capillary 
hypertension is responsible for the initiation 
and progression of renal disease in diabetes.12 
SGLT2 activity is an important factor in diabetic 
renal disease pathophysiology, as SGLT2 
transporters are upregulated due to enhanced 
SGLT2 gene expression and due to increased 
activation of the angiotensin II type 1 receptor 
generating increased SGLT2 transporters.12,21 
These actions worsen glomerular 
hyperfiltration and hypertension generating a 
1. 
Decreased insulin 
secretion 
2. Decreased incretin effect 
3. Increased lipolysis 
4. 
Increased renal glucose 
re-absorption 
5. Decreased glucose uptake 
6. 
Increased hepatic glucose 
production 
7. 
Increased glucagon 
secretion 
8. 
Neurotransmitter 
dysfunction 
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vicious cycle that propagates diabetic 
nephropathy.12 
By blocking the SGLT2 in the proximal tubule, 
SGLT2 inhibitors reverse the detrimental 
mechanisms that lead to glomerular 
hyperfiltration and hypertension. In fact, 
treatment with SGLT2 inhibitors is associated 
with a minimal, reversible decrease in the 
estimated glomerular filtration rate (eGFR) as 
a result of afferent arteriole 
vasoconstriction.12 This reduction in eGFR with 
SGLT2 inhibitors mimics that of angiotensin-
converting enzyme (ACE) inhibitors and 
angiotensin II receptor blockers (ARB).12 
CLINICAL BENEFITS 
SGLT2 inhibitors have a unique mechanism of 
action independent of insulin secretion and 
action. In addition, they provide a number of 
metabolic and haemodynamic effects that 
reduce the risk of cardiovascular and renal 
disease. 
Glycaemic Control 
SGLT2 inhibitors are intermediate glucose-
lowering agents, with mean HbA1c reductions 
of 0.6-1.1% when compared to placebo. A 
meta-analysis by Monami et al reported a 
reduction in HbA1c over 24 weeks that was 
more pronounced in patients who were 
younger, had a short history of diabetes 
duration and had a higher body mass index, 
HbA1c and fasting blood glucose level.5, 22 
Several studies have demonstrated that SGLT2 
inhibitors are non-inferior when compared to 
other anti-diabetic agents.4 
In a 78 week double-blind, placebo-controlled 
trial by Rosenstock et al, type 2 diabetic 
patients controlled solely on basal insulin who 
were prescribed empagliflozin required a 
reduced dose of insulin whereas the placebo 
group were observed to need an increased 
insulin dose.23 
In another 52 week, double-blind trial by 
Schernthaner et al, type 2 diabetics 
inadequately controlled on metformin and a 
sulfonylurea were randomly assigned to 
canagliflozin or sitagliptin. The HbA1c 
reduction was significantly greater with 
canagliflozin (-1.03%, -11.3mmol/mol) when 
compared to sitagliptin (-0.66%, -
7.2mmol/mol). Furthermore, participants on 
canagliflozin lost weight and had better 
systolic blood pressure readings when 
compared to sitagliptin treated patients (p 
value <0.001). Despite the better glycaemic 
control, subjects on canagliflozin suffered 
from increased genital tract infections. 
However, the overall results of this study have 
to be reviewed with caution since 38.5% of 
participants did not complete the study.24 
Hence, SGLT2 inhibitors provide additional 
glycaemic control in combination with both 
oral antidiabetic agents and insulin. 
Weight Loss 
Glycosuria leads to a negative caloric balance, 
resulting in a weight loss of circa 2-3kg. This 
has been demonstrated in 12-week trials of 
empagliflozin, canagliflozin and 
dapagliflozin.25  
This weight loss is usually apparent after 6 
weeks from the initiation of SGLT2 inhibitor 
therapy and the rate of weight loss gradually 
decreases until it stabilizes between weeks 26-
34.26 Most of the early decline in body weight 
with SGLT2 inhibition is due to the depletion of 
hepatic glycogen and the associated water 
loss. In the long term, mesenteric and 
subcutaneous adipose tissue loss contributes 
to further weight loss.16 
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Furthermore, in patients on insulin therapy, 
SGLT2 inhibitors reduce insulin dose 
requirements and may mitigate insulin-
induced weight gain. 
 
Decrease in Systolic and Diastolic Blood 
Pressure 
Decreases in systolic and diastolic blood 
pressure by 1.6-6.9mmHg and 0.88-3.5mmHg 
respectively were demonstrated with SGLT2 
inhibitor treatment.27 SGLT2 inhibitors lead to 
osmotic diuresis and mild natriuresis. This 
creates a reduced intravascular volume and an 
initial reduction in blood pressure readings. In 
the long term, weight loss and inhibition of the 
RAAS contributes to decreased blood pressure 
readings.27 
Cardiovascular Benefits 
Empagliflozin, canagliflozin and dapagliflozin 
have been associated with reduced 
cardiovascular morbidity and mortality in type 
2 diabetic patients with cardiovascular disease.  
The EMPA-REG OUTCOME study showed that 
empagliflozin reduces the risk of 
cardiovascular events. Although there were no 
significant between-group differences in the 
rates of myocardial infarction or non-fatal 
stroke, in the empagliflozin group there was a 
significantly lower death rate from 
cardiovascular causes (3.7% vs 5.9%), 
hospitalisation for heart failure (2.7% vs 4.1%) 
and death from any cause (5.7% vs 8.3%) when 
compared to the placebo group.28 
Furthermore, the divergence between the 
empagliflozin and placebo primary outcome 
curves was evident after only 3 months, 
suggesting the rapid effect of empagliflozin.29 
On the other hand, in the CANVAS trial it took 
1 year for canagliflozin treatment to show 
separation in the survival curve for major 
adverse cardiac events (MACE).29 However one 
should note that empagliflozin’s postulated 
rapid effect is a matter of debate and further 
studies are required to ascertain whether 
pharmacological intra-class effects exist.  
The CANVAS trial reported that canagliflozin 
decreased the rate of death from 
cardiovascular causes, non-fatal myocardial 
infarction or non-fatal stroke when compared 
with placebo occurring in 26.9 vs. 31.5 
participants per 1000 patient-years 
respectively with a p value of <0.001 for non-
inferiority and a p value of <0.02 for 
superiority. Like the EMPA-REG OUTCOME 
study, the reduction in occurrence of the 
individual components of the composite 
outcome in those subjects treated with 
canagliflozin were not statistically 
significant.30 
The results of the DECLARE-TIMI 58 trial are 
similar to the aforementioned studies. 
Dapagliflozin treatment did not result in a 
lower rate of MACE (p value of 0.17) but 
resulted in a lower death rate from 
cardiovascular causes and hospitalisation rates 
from heart failure when compared to placebo 
(p value of 0.005).31 
These studies demonstrated the significant 
cardiovascular benefit of empagliflozin, 
canagliflozin and dapagliflozin in a high risk 
population with established cardiovascular 
disease. Further studies are required to assess 
whether SGLT2 inhibitors will have such a 
beneficial effect on type 2 diabetics who do 
not have overt cardiovascular disease. 
Heart Failure 
As aforementioned, the EMPA-REG outcome 
and the DECLARE-TIMI 58 trial demonstrated 
reduced hospitalisation rates for heart 
failure.28, 31 In addition, a sub-analysis of the 
CANVAS trial revealed that canagliflozin 
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reduced the overall risk of heart failure events 
in patients with type 2 diabetes mellitus and 
high cardiovascular risk with no clear 
difference in effects on heart failure with 
reduced ejection fraction versus heart failure 
with preserved ejection fraction.32 
The natriuretric, glycosuric and metabolic 
effects of SGLT2 inhibitors benefit patients 
with heart failure. Furthermore, the above 
physiological effects have also been 
demonstrated in patients without diabetes 
mellitus.33 In fact, the U.S. Food and Drug 
Administration (FDA) has approved 
dapagliflozin as a treatment for heart failure 
with reduced ejection fraction in patients with 
or without type 2 diabetes.34   
Renal Benefits 
Empagliflozin and canagliflozin appear to 
reduce the progression of nephropathy. The 
secondary analysis of the EMPA-REG outcome 
revealed that patients on empagliflozin had a 
reduced risk of incident or worsening 
nephropathy when compared to the placebo 
group (12.7% vs 18.8% respectively).35 
Canagliflozin reduced the progression of 
albuminuria when compared to placebo in the 
CANVAS trial (89.4 vs. 128.7 participants per 
1000 patient years respectively). Additionally, 
the need for renal replacement therapy and 
death from renal causes occurred less 
frequently in the canagliflozin group when 
compared to placebo (5.5 vs. 9 patients per 
1000 patient-years).30 
RISKS ASSOCIATED WITH SGLT2 INHIBITORS 
Genital Tract Infections 
The most frequent adverse event of SGLT2 
inhibitors are genito-urinary tract infections.14 
There are several studies that concluded that 
SGLT2 inhibitor treatment in type 2 diabetics 
was linked with an increased incidence of 
urinary tract infections and genital mycotic 
infections.36-38 
Nicolle et al, (2015) showed that despite the 
increased risk of urinary tract infections in type 
2 diabetics treated with canagliflozin, there 
was no risk of serious or upper urinary tract 
infections.38 
However, this has been recently challenged 
and the U.S. FDA has issued warnings about 
cases of necrotizing fasciitis of the perineum in 
patients taking SGLT2 inhibitors. The FDA has 
received 12 reports of Fournier’s gangrene 
between March 2013 and May 2018.39 Patients 
with previous genital mycotic infections are at 
higher risk of developing such infections with 
dapagliflozin according to Thong et al (2018).40 
Patients should be informed of the risks of 
urinary and genital tract infections and advised 
to seek medical help early on if they develop 
any symptoms indicative of a urinary tract 
infection.  
Euglycaemic diabetic ketoacidosis 
In 2015, the FDA issued a safety warning 
regarding the risk of diabetic ketoacidosis in 
people with type 2 diabetes being managed 
with SGLT2 inhibitors.41 Fadini et al, (2017) 
analysed the diabetic ketoacidosis reports 
from the FDA adverse drug reporting (ADR) 
system and concluded that SGLT2 inhibitors 
are associated with diabetic ketoacidosis.42 
They also suggested that this is not limited to 
any particular demographic or co-morbid 
population and can occur after any duration of 
SGLT2 inhibitor use.42 
One possible pathophysiological event 
contributing to diabetic ketoacidosis in 
patients using SGLT2 inhibitors is due to their 
‘Robin-Hood effect’ (kindly refer to section 2.0 
The physiological actions of SGLT2 inhibitors).  
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Despite this, the European Medicines Agency 
(EMA) states that the benefits of SGLT2 
inhibitors continue to outweigh the risks in the 
treatment of type 2 diabetes.43 Physicians 
need to be made aware of the possible risk 
factors for diabetic ketoacidosis in patients 
treated with SGLT2 inhibitors. These include:  
• Insulin deficiency as in latent auto-
immune diabetes of adults14 
• Type 2 diabetics with evidence of low 
insulin secretory capability (labile 
diabetes control, lean body build or 
episodes of ketosis)14 
• Sudden reduction in the insulin dose44 
• Increased insulin requirements such as in 
post-operative cases and patients with an 
acute illness44 
• Alcoholism44 
• Starvation44 
• Dehydration 
If diabetic ketoacidosis is suspected, blood or 
urine ketone levels should be checked, even if 
the patient is normoglycaemic. If diabetic 
ketoacidosis is confirmed in a patient on SGLT2 
inhibitors, these should be stopped 
immediately. 44 
Lower limb amputations 
The FDA and EMA have issued warnings as 
there was an increased risk of leg and foot 
amputations with the use of canagliflozin in 
type 2 diabetics.6 This cautionary advice is 
mostly based on the CANVAS trial where 7 
cases of lower limb amputations out of 1000 
patients resulted in the 100mg canagliflozin 
group, compared to 3 cases of lower limb 
amputations out of 1000 patients in the 
placebo group.30 
Hence, with such evidence, it might be 
appropriate to avoid SGLT2 inhibitors in 
patients with peripheral vascular disease, 
neuropathy, active foot ulceration or a 
previous amputation.14 
Malignancy 
The potential carcinogenic effect of any drug 
cannot be assessed in short term trials.45 Initial 
data on dapagliflozin by HW Lin et al, 
suggested an association with male bladder 
cancers and female breast cancers.46 However, 
Wiviott et al, concluded that dapagliflozin 
therapy was not associated with increased 
bladder cancer risk.31 
A recent meta-analysis by Tang et al, 
demonstrated that SGLT2 inhibitors were not 
significantly associated with an overall 
increased risk of malignancy.  However, it was 
noted that there was an increased risk of 
bladder cancer with empagliflozin.45 
Skeletal Fractures 
SGLT2 inhibitors may affect bone 
metabolism.13 They can lead to increased renal 
reabsorption of phosphate resulting in an 
increased serum phosphate concentration. 
This hyperphosphataemia may promote 
parathyroid hormone secretion which in turn 
stimulates bone resorption in order to 
maintain serum calcium levels.6 In addition, 
SGLT2 inhibitors increase the serum 
concentration of fibroblast growth factor 23 
leading to bone disease and decreased 1,25 
dihydroxyvitamin D levels.  The overall effects 
are reduced calcium absorption from the gut 
and impaired bone calcification, hence 
increasing the overall risk of bone fractures.6 
There is conflicting evidence on the effect of 
SGLT2 inhibitors on bone metabolism. A meta-
analysis by Tang et al, does not support the 
harmful effects of SGLT2 inhibitors on bone 
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fractures.47 The fracture event rate was 1.59% 
in the SGLT2 inhibitors group and 1.56% in the 
control group.47  Watts et al, reported that the 
risk of fractures was increased with 
canagliflozin therapy.48 A small but statistically 
significant decrease in total hip bone mineral 
density was reported with canagliflozin when 
compared to placebo over a 2 year period (-
0.9% and -1.2% reduction in BMD in 
canagliflozin 100mg and 300mg respectively 
when compared to placebo).[49] There were 
no statistically significant changes in BMD at 
other sites (femoral neck, lumbar spine, distal 
forearm).49  Watts et al, concluded that the 
cause of the increased fracture risk with 
canagliflozin is unknown and extrinsic factors 
i.e.: the increased risk of falls due to 
orthostatic hypotension from the SGTL2 
inhibitor induced volume depletion is a more 
likely explanation.48 This risk is exacerbated in 
patients receiving diuretics.48 
With regards to this issue, further future 
safety monitoring from randomised controlled 
trials and studies on SGLT2 inhibitors on bone 
health and interaction with anti-resorptive 
therapy are still required.  
 
Table 2 Renal adjusted dosing of canagliflozin, dapagliflozin, empagliflozin and ertugliflozin 
 Canagliflozin Dapagliflozin Empagliflozin Ertugliflozin 
Starting Dose 100mg daily 5mg daily 10mg daily 5mg daily 
Maximum Dose 300mg daily 10mg daily 25mg daily 15mg daily 
Renal 
Adjustment 
eGFR >45-60: 
patients should 
not be initiated 
on canagliflozin 
but if they are 
already tolerating 
canagliflozin, use 
a maximum dose 
of 100mg daily  
eGFR <60: use 
is not 
recommended  
eGFR >45-60: 
patients should not 
be initiated on 
empagliflozin but if 
they are already 
tolerating 
empagliflozin, use a 
maximum dose of 
10mg daily 
eGFR <60: use 
is not 
recommended 
eGFR <45: use is 
contraindicated 
eGFR <45: use 
is 
contraindicated 
eGFR <45: use is 
contraindicated 
eGFR <45: use 
is 
contraindicated 
ESRD and 
Haemodialysis: 
use is 
contraindicated 
ESRD and 
Haemodialysis: 
use is 
contraindicated 
ESRD and 
Haemodialysis: use is 
contraindicated 
ESRD and 
Haemodialysis: 
use is 
contraindicated 
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Acute kidney injury 
The FDA had issued warnings about the risk of 
acute kidney injury for canagliflozin and 
dapagliflozin.14 However an analysis by 
Nadkarni et al, revealed that there was no 
evidence for an increased risk of acute kidney 
injury (AKI) associated with SGLT2 inhibitor use 
in patients with type 2 diabetes when 
compared to non-users over a 1 year follow-up 
in two large health systems.50 Nevertheless, 
renal function should be monitored prior to 
and during treatment with SGLT2 inhibitors.51 
Table 2 demonstrates the renal adjusted 
dosing of canagliflozin, dapagliflozin, 
empagliflozin and ertugliflozin.52 
INDICATIONS FOR SGLT2 INHIBITORS 
In the past, pharmacological management of 
diabetes has revolved around improving blood 
glucose and HbA1c levels. However, nowadays 
management is shifting towards prescribing 
antidiabetic agents that also provide 
cardiovascular benefits and reduce mortality. 
The 2019 update to the consensus report 
“Management of hyperglycaemia in type 2 
diabetes” by the American Diabetes 
Association (ADA) and the European 
Association for the Study of Diabetes (EASD) 
recommends prescribing SGLT2 inhibitors with 
proven cardiovascular benefit, after initiation 
of metformin and lifestyle changes in patients 
with established atherosclerotic 
cardiovascular disease (ASCVD). Moreover, the 
consensus report also recommends SGLT2 
inhibitor use among type 2 diabetics with 
ASCVD and heart failure. Another consensus 
recommendation regarding SGLT2 inhibitors is 
their use in type 2 diabetics with chronic kidney 
disease irrespective of cardiovascular disease 
if the eGFR permits, since they have been 
shown to provide renal outcome benefits.7 
Based on the benefits and adverse effects of 
SGLT2 inhibitors, the ideal type 2 diabetic 
candidate to receive SGLT2 inhibitor therapy 
requires the following characteristics: 
• young age22 
• eGFR >45 in empagliflozin and canagliflozin  
• eGFR >60 in dapagliflozin and ertugliflozin 
• heart failure 
• established atherosclerotic cardiovascular 
disease 
• obese/overweight22 
• hypertensive 
• no past/present history of frequent 
mycotic 
infections/urosepsis/pyelonephritis and 
indwelling urinary catheters14 
• no past history of peripheral vascular 
disease/neuropathy/active 
ulceration/gangrene14 
• no past history of diabetic ketoacidosis or 
unprovoked ketosis14 
Dapagliflozin was recently approved for the 
management of type 1 diabetes mellitus as an 
add on therapy with insulin, when the latter 
fails to achieve control in over-weight patients. 
Despite its significant improvement in 
glycaemic control and weight loss, there was a 
higher risk of DKA in patients with type 1 
diabetes.53 
SGLT2  INHIBITORS AND OTHER 
PHARMACOLOGICAL THERAPIES 
Before prescribing an SGLT2 inhibitor, 
physicians should discuss the benefits and 
adverse events related to these new 
therapeutic agents. The patient’s renal 
function and overall fluid status must be 
checked (by assessing blood pressure, jugular 
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venous pressure, skin turgor, chest 
auscultation for pulmonary oedema and lower 
limb oedema). A detailed history should be 
taken with a focus on any previous urinary 
tract infections or any features of peripheral 
vascular disease, while specifically looking for 
any active ulcerations. A urinalysis is 
commendable to screen against asymptomatic 
UTI and ketonuria. Renal function should be 
monitored pre- and post-treatment 
initiation.51 A moderate drop in eGFR is 
expected when starting an SGLT2 inhibitor.12 
Elderly individuals and other patients who are 
at risk of falls (e.g.: those suffering from 
orthostatic hypotension) would benefit from a 
bone mineral density test prior to SGLT2 
inhibitor therapy. Canagliflozin should be 
avoided in patients with osteoporosis as it was 
associated with a greater loss of bone mineral 
density over time.49 
Current diabetes treatment, anti-hypertensive 
treatment and diuretic therapy need to be 
specifically analysed, as treatment adjustment 
may be necessary.13 
Diabetic Treatment 
In patients receiving a biguanide or an incretin 
based therapy (DPP4-inhibitors or GLP-1 
receptor agonist), an SGLT2 inhibitor can be 
started without any adjustments. However, 
these patients should be advised to watch for 
possible loose stools or vomiting and ensure 
regular fluid intake. If such gastrointestinal 
effects occur, the biguanide or incretin based 
therapy’s dose should be lowered and vigorous 
fluid intake encouraged to reduce the risk of 
diabetic ketoacidosis. Ideally, treatment with 
SGLT2 inhibitors should be interrupted or 
postponed until there is correction of the fluid 
loss.  
In those patients on insulin or insulin 
secretagogues (sulfonylurea or glinides), 
treatment adjustment depends on the HbA1c 
level. If patients have an elevated HbA1c 
(>8.5%), then no dose adjustment is usually 
required. Patients with an HbA1c level of 
<8.5% may need to reduce their insulin/insulin 
secretagogue dose when initiating an SGLT2 
inhibitor.  
In all of the above settings, glucose monitoring 
is essential so that the diabetic treatment is 
titrated accordingly.13 
Diuretics 
Patients on diuretics may need diuretic dose 
adjustments. This decision should ideally be 
taken in conjunction with a cardiologist, 
especially in cases of chronic heart failure.13 
Anti-hypertensive Treatment 
Patients who are >65 years of age, suffer from 
atrial fibrillation or frequent syncopal events 
or orthostatic hypotension or who have a 
blood pressure <140/80mmHg, may require a 
lower anti-hypertensive dose if an SGLT2 
inhibitor is prescribed. In these patients, blood 
pressure should be monitored on a weekly 
basis initially and the dose of anti-hypertensive 
treatment adjusted as necessary.13 
In addition, since SGLT2 inhibitors cause a 
moderate drop in eGFR, patients taking 
nephrotoxic agents (ACE-i, ARB, NSAIDs, 
diuretics, digoxin and aminoglycosides) should 
be closely monitored so as to avoid acute 
kidney injury.  
CONCLUSION 
SGLT2 inhibitors represent a new class of oral 
antidiabetic medications that not only target 
glucose homeostasis but through other 
pleiotropic effects offer cardiac and renal 
protection. The 2019 update to the consensus 
report “Management of hyperglycaemia in 
type 2 diabetes” by the ADA and EASD 
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recommends SGLT2 inhibitor use with proven 
cardiovascular benefit, after first line therapy 
with metformin and lifestyle changes. In 
addition, SGLT2 inhibitor use is recommended 
in patients with atherosclerotic cardiovascular 
disease with co-existent heart failure and in 
patients with type 2 diabetes and chronic 
kidney disease (CKD) (irrespective of their 
cardiovascular disease status) as they reduce 
CKD progression.7 Empagliflozin has 
demonstrated a wide spectrum of beneficial 
effects ranging from reducing kidney disease 
progression, hospitalisation for heart failure 
and cardiovascular and all-cause mortality.28 
Although the trials offer promising data, 
SGLT2 inhibitor use requires careful patient 
selection, so that those that will benefit from 
such therapy will be prescribed these 
medications.  Patients on this treatment need 
regular monitoring to avoid or pick up adverse 
effects early on.  
KEY POINTS 
• SGLT2 inhibitors are a relatively new class 
of oral antidiabetic agents with a unique 
mechanism of action, independent of 
insulin secretion and action. 
• SGLT2 inhibitors provide an intermediate 
glucose-lowering effect by inducing 
glycosuria and in addition offer cardiac 
and renal outcome benefits through 
other pleiotropic effects. 
• SGLT2 inhibitors are associated with a 
number of risks including: genital tract 
infections, euglycaemic diabetic 
ketoacidosis, lower limb amputations, 
skeletal fractures, risk of malignancy and 
acute kidney injury. 
• Empagliflozin has demonstrated a wide 
spectrum of beneficial effects including 
the following: a reduction in progression 
of kidney disease, a decrease in hospital 
admissions for heart failure and also a 
reduction in cardiovascular and all-cause 
mortality. 
• When it comes to SGLT2 inhibitors, 
physicians need to move away from a one-
size-fits-all approach towards a more 
personalized patient-centred 
management. Despite the multiple 
benefits SGLT2 inhibitors offer, their 
prescription requires careful assessment 
by the prescribing physician to identify 
those patients who would benefit from 
such drugs so as to ensure a reduced risk 
of adverse events.
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